ArticleCancers2023
Prostate Cancers Invisible on Multiparametric MRI: Pathologic Features in Correlation with Whole-Mount Prostatectomy.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Prospective Validation of an Automated Hybrid Multidimensional MRI Tool for Prostate Cancer Detection Using Targeted Biopsy: Comparison with PI-RADS-based Assessment.Radiology. Imaging cancer · 2025Trial
- Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.NMR in biomedicine · 2026Article
- The accuracy of transperineal template-guided mapping biopsy in patients with negative magnetic resonance imaging.Prostate international · 2026Article
- Analysis of risk factors for MRI-invisible prostate cancer-the significance of AGGF1 immunohistochemical detection and PSAD.The Canadian journal of urology · 2026Article
- Does It Make Sense to Perform Prostate Magnetic Resonance Imaging in Men with Normal PSA (<4 ng/mL)?Cancers · 2026Article
- In-bore MRI-guided prostate biopsy: current evidence, clinical applications, and future directions.Polish journal of radiology · 2026Review
- Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease.Scientific reports · 2025Article
- Mapping of prostate cancer microvascular patterns using super-resolution ultrasound imaging.European radiology experimental · 2025Article
- The impact of benign tissue within cancerous regions in the prostate: Characterizing sparse and dense prostate cancers on whole-mount histopathology and on multiparametric MRI.Magnetic resonance imaging · 2024Article
- Article
- MRI-based virtual pathology of the prostate.Magma (New York, N.Y.) · 2024Review
- Exploring the potential ofProstate international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
We investigated why some prostate cancers (PCas) are not identified on multiparametric MRI (mpMRI) by using ground truth reference from whole-mount prostatectomy specimens. A total of 61 patients with biopsy-confirmed PCa underwent 3T mpMRI followed by prostatectomy. Lesions visible on MRI prospectively or retrospectively identified after correlating with histology were considered "identified cancers" (ICs). Lesions that could not be identified on mpMRI were considered "unidentified cancers" (UCs). Pathologists marked the Gleason score, stage, size, and density of the cancer glands and performed quantitative histology to calculate the tissue composition. Out of 115 cancers, 19 were unidentified on MRI. The UCs were significantly smaller and had lower Gleason scores and clinical stage lesions compared with the ICs. The UCs had significantly (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.